Sélectionner la langue
BAFFR
BAFFR Informations sur la molécule
| Nom anglais | B-cell activating factor receptor | Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 14 | Alias de la cible | BAFFR，B Cell-Activating Factor Receptor，Prolixin，BROMIX，CD268，Tumor Necrosis Factor Receptor Superfamily， Member 13C，Tumor Necrosis Factor Receptor Superfamily Member 13C，BR3，CVID4，CD268 Antigen，BAFF Receptor，B-Cell Activation Factor Receptor，BAFF-R，TNF Receptor Superfamily Member 13C，BLyS Receptor 3，B-Cell-Activating Factor Receptor，TNFRSF13C |
| Phase de R&D la plus avancée | NDA/BLA | ||
| Nom anglais | B-cell activating factor receptor |
| Alias de la cible | BAFFR，B Cell-Activating Factor Receptor，Prolixin，BROMIX，CD268，Tumor Necrosis Factor Receptor Superfamily， Member 13C，Tumor Necrosis Factor Receptor Superfamily Member 13C，BR3，CVID4，CD268 Antigen，BAFF Receptor，B-Cell Activation Factor Receptor，BAFF-R，TNF Receptor Superfamily Member 13C，BLyS Receptor 3，B-Cell-Activating Factor Receptor，TNFRSF13C |
| Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 14 |
| Phase de R&D la plus avancée | NDA/BLA |
BAFFR Liste de produits
- Attribut
Protein (12)
- Bibliothèque de produits
En ligne (12)
- Espèces
Mouse (3)Human (6)Cynomolgus (2)Rat (1)
- Étiquette
Fc Tag & Avi Tag (2)Fc Tag (3)Llama IgG Fc Tag (1)His Tag (5)His Tag & Avi Tag (1)
- Marqueur
Biotin-labeled (3)Unconjugated (8)PE Labeled (1)
Ajouter au panier
Quantité totale12
- 1
- 2
BAFFRContexte de la molécule
BAFF receptor (B-cell activating factor receptor, BAFF-R), also known as tumor necrosis factor receptor superfamily member 13C (TNFRSF13C), is a membrane protein of the TNF receptor superfamily which recognizes BAFF. B-cell activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of BAFF in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells.
BAFFRAlias de la molécule
BAFFR,TNFRSF13C,BROMIX,CD268,CVID4,prolixin,BAFF-R
Plateforme de commerce de projets d'anticorps
| Nom du projet | Phase du projet | Type de molécule | Source de molécule | Domain thérapeutique | Indication |
|---|---|---|---|---|---|
| BAFFR&CD3 BsAb - 01 | PCC | Bispecific | Humanized Mouse,Nanobody | Hematological Malignancy,AutoImmunity | Blood tumor,Autoimmune disease |
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Fully Human BAFF-R Chimeric Antigen Receptor T-Cell (Taihe Chunyu) | Phase 2 Clinical | Hebei Tahoe Chunyu Biotechnology Co Ltd | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Waldenstrom Macroglobulinemia | Details | |
| Anti-BAFFR CAR T therapy(The General Hospital Of Tianjin Medical University) | BAFFR CART | Phase 2 Clinical | The General Hospital Of Tianjin Medical University | Myasthenia Gravis; Myositis; Neuromyelitis Optica; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Details |
| ESG-206 | ESG-206 | Phase 2 Clinical | Shanghai Escugen Biotechnology Co Ltd | Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Neoplasms; Purpura, Thrombocytopenic, Idiopathic; Sjogren's Syndrome | Details |
| dual anti-CD19/anti-BAFF CAR T-cell therapy (Shanghai YaKe Biotechnology/Zhejiang University) | Phase 1 Clinical | Shanghai Yake Biotechnology Co Ltd | Autoimmune Diseases; Dermatomyositis; Lupus Erythematosus, Systemic; Nephritis; Neuromyelitis Optica; Scleroderma, Systemic | Details | |
| SSS-68 | SSS68; SSS-68 | Phase 1 Clinical | Shenyang Sunshine Pharmaceutical Co Ltd | Glomerulonephritis, IGA | Details |
| BAFF-R CAR-T cells therapy (Topcel-KH Pharmaceutical) | Phase 1 Clinical | Jiangsu Topcel-KH Pharmaceutical Co Ltd | Lymphoma, B-Cell | Details | |
| BAFFR CAR-T cell therapy (Bio-gene Technology) | Phase 1 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| LY-4152199 | LY-4152199; LY4152199 | Phase 1 Clinical | Eli Lilly And Company | Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells therapy(Mayo Clinic) | MC10029; MC-10029 | Phase 1 Clinical | Mayo Clinic | Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell | Details |
| CD19-BAFF Targeted CAR T-cells Therapy(YaKe Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd, Zhejiang University | Autoimmune Diseases; Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| KD-6005 | KD-6005; KD6005 | Phase 1 Clinical | Shanghai Celgen Bio-Pharmaceutical Co Ltd, Shanghai Kanda Bio-Technology Co Ltd | Arthritis, Rheumatoid | Details |
| Aritinercept | AUR-200; AUR200 | Phase 1 Clinical | Thunderbolt Pharma Inc | Autoimmune Diseases | Details |
| JH-013 | JH-013 | Phase 1 Clinical | Biotech Pharmaceuticals Co Ltd | Arthritis, Rheumatoid; Hematologic Neoplasms; Lupus Erythematosus, Systemic; Sjogren's Syndrome | Details |
| BAFFR-CAR T cell therapy (PeproMene Bio) | PMB-101; PMB-CT01 | Phase 1 Clinical | City Of Hope National Medical Center, PeproMene Bio Inc | Leukemia, Biphenotypic, Acute; Lymphoma, B-Cell; Lymphoma, Follicular; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments cliniques
Partager vers :